 Dr Gilles Gallant,
Vice President Clinical Oncology Human Genome Sciences Dr. Gilles Gallant joined Human Genome Sciences Inc. (Rockville, Maryland, USA) in 2002 as Vice President, Clinical Oncology. Human Genome Sciences (HGS) is a global biopharmaceutical company whose mission is to create and develop novel therapies that can extend and improve the quality of life of patients.
Prior to joining HGS, Dr. Gallant was Director of Clinical Oncology at Bristol-Myers Squibb Pharmaceutical Research Institute in Wallingford, Connecticut, USA. Dr. Gallant joined Bristol-Myers Squibb in 1991, and advanced through a succession of clinical oncology research management positions in Canada (1991-1995), Europe (1995-1999) and the United States (1999-2002). He played a key role in designing and directing worldwide registrational and non-registrational clinical trials of Bristol-Myers Squibb’s oncology products, including Taxol®, in the USA, Europe and Canada.
At HGS, Dr. Gallant is responsible for establishing the strategy and leading the implementation of the clinical development of all oncology assets including the agonistic monoclonal antibodies mapatumumab and lexatumumab (targeting the TRAIL receptors), HGS1029 (a small molecule IAP inhibitor) and other agents in development. He is a member of HGS’ Operating Committee, Senior Management Team, Research and Development External Opportunities Review Team and Product Safety Committee.
Dr. Gallant received his doctorate in medicinal chemistry and bachelor’s degree in pharmacy from the Université de Montréal in Montréal (Québec) Canada. He has co-authored numerous scientific abstracts and peer-reviewed publications in the oncology research field, and is an active member of the Ordre des Pharmaciens du Québec (OPQ), the American Chemical Society (ACS), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the American Society of Hematology (ASH), the International Association for the Study of Lung Cancer (IASLC) and the Society of Nuclear Medicine (SNM).Appearing: DAY 3 THURSDAY 23 SEPTEMBER – CLINICAL TRIALS, COLLABORATIONS & COMBINATION THERAPY 9.10am Clinical development strategies for targeted cancer therapy
- Medical and scientific strategies for clinical development of efficacious oncology drugs – what information needs to be obtained and how to get it.
- Incorporating targeted cancer therapy into these development strategies.
- Solutions for overcoming patient selection and clinical end point challenges.
Dr Gilles Gallant, Vice President Clinical Oncology,
Human Genome Sciences 3.30pm Extended panel discussion with Q&A: how is big pharma driving targeted cancer therapies to the forefront of the oncology industry?
- Scientifically – what are the areas of greatest potential for further development? Which industry profiles hold the key to developing them?
- Clinically – has the time come to readdress how oncology trials are planned and executed? What are the alternatives?
- Commercially – how can we integrate science and clinical outcomes into a successful business plan that meets the requirements of drug developers, patients, clinicians and government?
Vice President Oncology R&D,
Biogen Idec Senior Vice President R&D, Global Head Therapeutic Area Oncology,
Merck Serono Dr Gilles Gallant, Vice President Clinical Oncology,
Human Genome Sciences Global Brand Physician,
AstraZeneca Pharmaceuticals |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
